# CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke

Study · id `cardio:ct-nct06078215` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06078215](<https://clinicaltrials.gov/study/NCT06078215>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06078215

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 350 participants.

## Technical summary

Registry record NCT06078215. Randomized; no masking; primary purpose treatment. Start 2023-01-10 (actual); primary completion 2025-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 350 participants (planned count; ClinicalTrials.gov record NCT06078215, source copy `cardio:ctgov-nct06078215-2023-10-13`, retrieved 2026-10-26)
- Started: 2023-01-10 (actual) (ClinicalTrials.gov record NCT06078215, source copy `cardio:ctgov-nct06078215-2023-10-13`, retrieved 2026-10-26)
- Primary completion: 2025-01-31 (anticipated) (ClinicalTrials.gov record NCT06078215, source copy `cardio:ctgov-nct06078215-2023-10-13`, retrieved 2026-10-26)
- Completion: 2025-03-31 (anticipated) (ClinicalTrials.gov record NCT06078215, source copy `cardio:ctgov-nct06078215-2023-10-13`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT06078215, source copy `cardio:ctgov-nct06078215-2023-10-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06078215-2023-10-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke
- Acronym: CERBERUS
- Condition: Acute Ischemic Stroke
- Intervention (Combination product): Cerebrolysin
- Lead sponsor: Poznan University of Medical Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Poznan University of Medical Sciences (`cardio:org-poznan-university-of-medical-sciences`)

## Provenance

Content hash: 1112ea84c9dd8bb3ea48f4221b94a86f26e798aa28d686157d866e6717261b87
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
